Renate Starr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Renate Starr has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Christine E. Brown
Department of Hematology & Hematopoietic Cell Transplantation (T Cell Therapeutics Research Laboratories), City of Hope Beckman Research Institute and Medical Center, Duarte, CA 91010, USA
32 shared publications Brenda Aguilar
22 shared publicationsBehnam Badie
20 shared publicationsStephen J. Forman
20 shared publicationsDarya Alizadeh
18 shared publicationsDongrui Wang
18 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S1| Amino acid substitution for meCAR design and affinity characterization of meCAR variants.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S1| Amino acid substitution for meCAR design and affinity characterization of meCAR variants.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key platform where fragment antigen-binding (Fab) regions of antibodies are modified to bind a small cyclic peptide termed meditope peptide (meP). We developed a panel of meditope-enabled Fab-based CARs (meCAR), which showed selective binding to the meP and comparable activity with traditional single-chain variable fragment–based CARs. Focusing on HER2-targeted meCARs for evaluating platform utility, we exploited the modularity of the meditope platform to detect meCAR T cells using meP-fused fluorescent agents, promote meCAR T-cell expansion via meP-fused IL15 cytokine, and broaden tumor antigen targeting through meP-fused antibodies to address tumor heterogeneity. These findings establish the meditope technology as a versatile strategy to augment CAR T-cell functionality and overcome key limitations of current CAR-based therapies.See related Spotlight, p. 1536
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key platform where fragment antigen-binding (Fab) regions of antibodies are modified to bind a small cyclic peptide termed meditope peptide (meP). We developed a panel of meditope-enabled Fab-based CARs (meCAR), which showed selective binding to the meP and comparable activity with traditional single-chain variable fragment–based CARs. Focusing on HER2-targeted meCARs for evaluating platform utility, we exploited the modularity of the meditope platform to detect meCAR T cells using meP-fused fluorescent agents, promote meCAR T-cell expansion via meP-fused IL15 cytokine, and broaden tumor antigen targeting through meP-fused antibodies to address tumor heterogeneity. These findings establish the meditope technology as a versatile strategy to augment CAR T-cell functionality and overcome key limitations of current CAR-based therapies.See related Spotlight, p. 1536
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S5| Binding of meP-αCD20 on tumor triggers dual-targeting of HER2 meCAR T cells.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S5| Binding of meP-αCD20 on tumor triggers dual-targeting of HER2 meCAR T cells.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S6| Dual-targeting of HER2-meCAR T cells by meP-αPD-L1 and meP-αCD20.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S6| Dual-targeting of HER2-meCAR T cells by meP-αPD-L1 and meP-αCD20.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S7| Optimized meP-αCD20 Fab shows improved antitumor activity.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S7| Optimized meP-αCD20 Fab shows improved antitumor activity.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig.S4| meP-IL15s-mediated enrichment of meCAR T cells and assessment of toxicity.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig.S4| meP-IL15s-mediated enrichment of meCAR T cells and assessment of toxicity.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S3| Design and characterization of meditope-enabled CARs targeting additional antigens.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S3| Design and characterization of meditope-enabled CARs targeting additional antigens.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S2| in vivo efficacy of HER2 meCAR T cells in an OVCAR-3 xenograft model.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S2| in vivo efficacy of HER2 meCAR T cells in an OVCAR-3 xenograft model.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (10) , 1553-1569
Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key platform where fragment antigen-binding (Fab) regions of antibodies are modified to bind a small cyclic peptide termed meditope peptide (meP). We developed a panel of meditope-enabled Fab-based CARs (meCAR), which showed selective binding to the meP and comparable activity with traditional single-chain variable fragment–based CARs. Focusing on HER2-targeted meCARs for evaluating platform utility, we exploited the modularity of the meditope platform to detect meCAR T cells using meP-fused fluorescent agents, promote meCAR T-cell expansion via meP-fused IL15 cytokine, and broaden tumor antigen targeting through meP-fused antibodies to address tumor heterogeneity. These findings establish the meditope technology as a versatile strategy to augment CAR T-cell functionality and overcome key limitations of current CAR-based therapies. See related Spotlight, p. 1536
- 4 August 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (10) , 1553-1569
Open AccessMeditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key platform where fragment antigen-binding (Fab) regions of antibodies are modified to bind a small cyclic peptide termed meditope peptide (meP). We developed a panel of meditope-enabled Fab-based CARs (meCAR), which showed selective binding to the meP and comparable activity with traditional single-chain variable fragment–based CARs. Focusing on HER2-targeted meCARs for evaluating platform utility, we exploited the modularity of the meditope platform to detect meCAR T cells using meP-fused fluorescent agents, promote meCAR T-cell expansion via meP-fused IL15 cytokine, and broaden tumor antigen targeting through meP-fused antibodies to address tumor heterogeneity. These findings establish the meditope technology as a versatile strategy to augment CAR T-cell functionality and overcome key limitations of current CAR-based therapies. See related Spotlight, p. 1536
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies
Supplementary Methods, Figures S1-S14, Table legends, and References
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies
Supplementary Methods, Figures S1-S14, Table legends, and References